ALK-abello A/S Class B
Recent
price
P/E
ratio
div
yld
0.67%
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company primarily engaged in the development, manufacturing, and marketing of allergy immunotherapy (AIT) products for the prevention and treatment of allergic diseases. The company’s core product portfolio includes sublingual immunotherapy tablets (SLIT-tablets) for allergies such as grass pollen (GRAZAX/GRASTEK), ragweed pollen (RAGWITEK), and house dust mite (ACARIZAX/ITULATEK), as well as subcutaneous immunotherapy (SCIT) allergy vaccines targeting a broad spectrum of allergens including pollens, molds, mites, pets, bees, and wasps. ALK also offers emergency treatments such as adrenaline autoinjectors for anaphylaxis management, allergy diagnostic kits including skin prick tests, and bulk allergen extracts primarily marketed to allergy specialists in the United States. Operating globally with presence in 46 countries across Europe, North America, and Asia-Pacific, the company manufactures products at facilities in Denmark, France, Spain, and the United States. Founded in 1923 and headquartered in Hørsholm, Denmark, ALK is one of the leading global providers in allergy immunotherapy. In recent years, ALK has focused on expanding its pipeline of patient-friendly allergy treatments, notably advancing its portfolio of SLIT-tablets and pursuing strategic collaborations including a 2024 global licensing deal to commercialize the neffy® adrenaline nasal spray (excluding the USA, Australia, New Zealand, Japan, and China) with U.S.-based ARS Pharmaceuticals, enhancing its emergency treatment offerings. Furthermore, in 2025 ALK entered a partnership with Changchun GeneScience Pharmaceutical Co. (GenSci) to expand the market for its house dust mite allergy immunotherapy products in China, aiming to accelerate commercial uptake and innovation collaboration across allergic diseases between the companies for China and international markets. ALK also recently expanded its Executive Leadership Team to support its growth strategy and commercial execution across key global markets. These initiatives complement ALK’s ongoing commitment to research and development, driving innovation in allergy care and expanding access to its immunotherapy treatments globally.
Company News
ALK-Abelló A/S (AKBLF) Q2 2026 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q1 2026 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Shareholder/Analyst Call Transcript
ALK-Abelló A/S (AKBLF) Q4 2025 Earnings Call Transcript
Invitation to the presentation of ALK's annual report 2025 on Friday, 20 February 2026
ALK-Abelló A/S (OTC:AKBLF) Trading Up 1.8% – What’s Next?
ALK-Abelló A/S (AKBLF) Q3 2025 Earnings Call Transcript
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
ALK-Abelló A/S (AKBLF) Q2 2025 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q1 2025 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q4 2024 Earnings Call Transcript
ALK-Abelló A/S (AKBLF) Q3 2024 Earnings Conference Call Transcript
ALK-Abelló A/S (AKBLF) Q1 2024 Earnings Call Transcript